Compare McKesson Corporation (MCK) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vale SA — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Vale SA trades at $14.3 (market cap $59.07B). The key difference: McKesson Corporation is the larger of the two by market cap, and Vale SA pays the higher dividend (8.93%). Which is the better fit depends on your goals.
| MCK | VALE | |
|---|---|---|
Market Cap | $97.35B | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $17.82 |
52-Week Low | $659.01 | $9.53 |
Enterprise Value | $101.98B | $75.99B |
Dividend Yield | 0.39% | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VALE trades at $14.08, down 0.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported $38.4B revenue for 2025 with net income of $2.35B, though earnings have missed expectations in two of the last three quarters. Recent news highlights governance challenges and a $2.6B decarbonization investment plan announced in June 2026.
While analyst consensus remains cautiously optimistic with a $17.63 price target, declining profit margins and recent earnings misses present headwinds. The stock offers value with reasonable P/E and EV/EBITDA multiples, but investors face risks from commodity price volatility and execution challenges in the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
